A widely-used vaccine does not offer protection against gonorrhea, according to the results of a major clinical trial released Wednesday. The study, published by the Kirby Institute at UNSW Sydney, found the meningococcal B vaccine (4CMenB) had no effect on preventing the sexually transmitted infection among gay and bisexual men – a population at particularly high risk. The findings challenge previous observational studies that suggested a potential link between the vaccine and reduced gonorrhea rates.
The randomized, double-blind, placebo-controlled trial, dubbed ‘GoGoVax,’ involved 587 gay and bisexual men. Participants received either the 4CMenB vaccine or a saline placebo, and were monitored for gonorrhea acquisition over a period of time. Researchers found that the incidence of gonorrhea was virtually identical – around 48 percent per year – in both groups, indicating the vaccine provided no protective benefit. The results were presented today by Professor Kate Seib from Griffith University at the Conference on Retroviruses and Opportunistic Infections in Denver, Colorado.
The study’s findings are particularly relevant given the growing public health concern surrounding gonorrhea, and the increasing prevalence of antibiotic-resistant strains. Gonorrhea infections are rising globally, and treatment options are becoming limited. The initial interest in the meningococcal B vaccine as a potential preventative measure stemmed from observations that vaccinated individuals appeared to have lower rates of gonorrhea. However, this new research demonstrates that these earlier observations were likely influenced by other factors.
Understanding Observational Studies vs. Randomized Controlled Trials
The ‘GoGoVax’ trial was initiated specifically to investigate the conflicting evidence from earlier observational studies. Professor Andrew Grulich from the Kirby Institute explained that observational studies can be misleading due to “confounding factors” – variables that aren’t accounted for and can skew results. For example, studies comparing vaccination rates between those with and without gonorrhea might not consider other behavioral differences between the groups.
“Some case-control studies have compared the meningococcal B vaccination history of people who have gonorrhea to the vaccination history of people who have chlamydia,” Professor Grulich said. “In these studies, people who acquired gonorrhea had lower 4CMenB vaccination rates than expected, suggesting that the vaccine may have prevented gonorrhea. However, other confounding factors might explain the differences in vaccine history between the other two groups.”
Randomized controlled trials (RCTs), like ‘GoGoVax,’ are considered the gold standard in medical research since they minimize the impact of confounding factors through random assignment of participants to different groups. “In GoGoVax, our data demonstrate that good-quality randomisation was achieved, and people randomised to receive vaccine or placebo had balanced levels of confounding factors,” Professor Grulich stated. “A properly conducted RCT provides the strongest possible evidence of a cause-and-effect relationship.”
Implications for Prevention and Future Research
While the findings are disappointing, researchers emphasize that the meningococcal B vaccine remains a safe and effective tool for preventing meningococcal disease. The vaccine was approved for leverage in Australia in 2013 and continues to be recommended for individuals at risk of meningococcal infection.
“We want men who have received the 4CMenB vaccine in the hope of gonorrhea prevention to realize that the vaccine is very safe and they will have protection against some meningococcal strains,” Professor Grulich clarified. “However, these men will need to explore other options for prevention of acquisition of gonorrhea, such as condoms and regular testing. Services like sexual health clinics and community-based testing services are strong pillars of prevention.”
The study focused on gay and bisexual men with a recent history of gonorrhea or syphilis, as this group is disproportionately affected by the infection. Researchers acknowledge that the results may not be generalizable to other populations. Brent Mackie, Director of Policy, Strategy and Research at ACON, a community health organization, emphasized the importance of continued research. “Research like this is vital because it helps give our communities the clarity we need. Findings help us refine our approach in preventing the transmission of STIs,” he said.
The ‘GoGoVax’ trial builds on the findings of a smaller, open-label trial called DOXYVAC, which also showed no effect of the 4CMenB vaccine on gonorrhea prevention. Taken together, these studies provide strong evidence against the vaccine’s efficacy for this purpose in high-risk men.
What’s Next in Gonorrhea Prevention?
The search for an effective gonorrhea vaccine remains a critical public health priority. Researchers are exploring other potential vaccine candidates and prevention strategies. In the meantime, public health officials continue to recommend proven methods of prevention, including safe sex practices, regular testing, and prompt treatment of infections.
The Kirby Institute will continue to monitor gonorrhea trends and support research aimed at developing new prevention tools. The next steps involve investigating alternative vaccine approaches and refining existing prevention strategies to address the growing challenge of antibiotic-resistant gonorrhea.
This article provides information for educational purposes only and is not a substitute for professional medical advice. If you have concerns about sexually transmitted infections, please consult with a healthcare provider.
